Post Menopausal Osteoporosis - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 80 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Post Menopausal Osteoporosis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Post Menopausal Osteoporosis - Pipeline Review, H2 2014', provides an overview of the Post Menopausal Osteoporosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Post Menopausal Osteoporosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post Menopausal Osteoporosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Post Menopausal Osteoporosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Post Menopausal Osteoporosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Post Menopausal Osteoporosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Post Menopausal Osteoporosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Post Menopausal Osteoporosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Post Menopausal Osteoporosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Post Menopausal Osteoporosis Overview 7
Therapeutics Development 8
Pipeline Products for Post Menopausal Osteoporosis - Overview 8
Pipeline Products for Post Menopausal Osteoporosis - Comparative Analysis 9
Post Menopausal Osteoporosis - Therapeutics under Development by Companies 10
Post Menopausal Osteoporosis - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Post Menopausal Osteoporosis - Products under Development by Companies 14
Post Menopausal Osteoporosis - Companies Involved in Therapeutics Development 15
Amgen Inc. 15
Eli Lilly and Company 16
Merck & Co., Inc. 17
Pfizer Inc. 18
Osteologix Holdings Plc. 19
Unigene Laboratories, Inc. 20
Radius Health, Inc. 21
Chronos Therapeutics Limited 22
Paras Biopharmaceuticals Finland Oy 23
Post Menopausal Osteoporosis - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Combination Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
(bazedoxifene acetate + conjugated estrogens) - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
denosumab - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
romosozumab - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
odanacatib - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
calcitonin - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
NBS-101 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
abaloparatide - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
blosozumab - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
RDC-5 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
teriparatide biosimilar - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Post Menopausal Osteoporosis - Recent Pipeline Updates 54
Post Menopausal Osteoporosis - Dormant Projects 68
Post Menopausal Osteoporosis - Discontinued Products 69
Post Menopausal Osteoporosis - Product Development Milestones 70
Featured News & Press Releases 70
Apr 01, 2014: Eli Lilly and Company Expands Authorized Generic Agreements with Prasco 70
Mar 04, 2014: Teva Announces Approval of Generic Evista Tablets 60 mg in the United States 70
Jan 09, 2014: Radius Announces Positive Topline Data From Phase 2 Study of Abaloparatide (BA058) for Postmenopausal Osteoporosis Using Two Delivery Systems 70
Dec 31, 2013: Romosozumab Phase 2 Data Published In New England Journal Of Medicine Show Significant Increases In Bone Mineral Density At Both Spine And Hip 72
Nov 04, 2013: EffRx Pharmaceuticals Announces Distribution Partnership with Ascendancy Healthcare 73
Oct 04, 2013: Amgen Presents Data From Several Prolia Studies At ASBMR 74
Oct 04, 2013: Amgen Presents Abstracts From Romosozumab Studies At ASBMR 75
Oct 03, 2013: Pfizer Announces FDA Approval Of DUAVEE For The Treatment Of Moderate-To-Severe Vasomotor Symptoms Associated With Menopause And The Prevention Of Postmenopausal Osteoporosis 75
Aug 29, 2013: Launch of the New Agent for Osteoporosis "Bonviva Injection 1 mg Syringe" 77
May 14, 2013: Treatment With Two Osteoporosis Drugs Better At Increasing Bone Density Than Single-drug Therapy, Study Finds 77
Appendix 79
Methodology 79
Coverage 79
Secondary Research 79
Primary Research 79
Expert Panel Validation 79
Contact Us 80
Disclaimer 80

List of Tables
Number of Products under Development for Post Menopausal Osteoporosis, H2 2014 8
Number of Products under Development for Post Menopausal Osteoporosis - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Comparative Analysis by Late Stage Development, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Post Menopausal Osteoporosis - Pipeline by Amgen Inc., H2 2014 15
Post Menopausal Osteoporosis - Pipeline by Eli Lilly and Company, H2 2014 16
Post Menopausal Osteoporosis - Pipeline by Merck & Co., Inc., H2 2014 17
Post Menopausal Osteoporosis - Pipeline by Pfizer Inc., H2 2014 18
Post Menopausal Osteoporosis - Pipeline by Osteologix Holdings Plc., H2 2014 19
Post Menopausal Osteoporosis - Pipeline by Unigene Laboratories, Inc., H2 2014 20
Post Menopausal Osteoporosis - Pipeline by Radius Health, Inc., H2 2014 21
Post Menopausal Osteoporosis - Pipeline by Chronos Therapeutics Limited, H2 2014 22
Post Menopausal Osteoporosis - Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2014 23
Assessment by Monotherapy Products, H2 2014 24
Assessment by Combination Products, H2 2014 25
Number of Products by Stage and Target, H2 2014 27
Number of Products by Stage and Mechanism of Action, H2 2014 29
Number of Products by Stage and Route of Administration, H2 2014 31
Number of Products by Stage and Molecule Type, H2 2014 33
Post Menopausal Osteoporosis Therapeutics - Recent Pipeline Updates, H2 2014 54
Post Menopausal Osteoporosis - Dormant Projects, H2 2014 68
Post Menopausal Osteoporosis - Discontinued Products, H2 2014 69